ImmunoGen (IMGN) Stock Price, News & Analysis

Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Key Stats

• Today's Range: $31.23 to $31.23
• 50-Day Range: $31.23 to $31.23
• 52-Week Range: $3.61 to $31.25
• Volume: 40 shs
• Average Volume: 8.78 million shs
• Market Capitalization: $8.32 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMGN Stock Analysis - Frequently Asked Questions

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.14. ImmunoGen's revenue was up 485.9% on a year-over-year basis.

Does ImmunoGen have any subsidiaries?

ImmunoGen subsidiaries include these companies: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoGen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), General Electric (GE), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 7/31/2023
• Today: 1/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMGN
• CUSIP: 45253H10
• CIK: 855654
• Web: www.immunogen.com
• Phone: (781) 895-0600
• Fax: 781-895-0611
• Employees: 277
• Year Founded: 1981

Profitability

• EPS (Most Recent Fiscal Year): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 390.38
• P/E Growth: N/A
• Net Income: $-222,930,000.00
• Net Margins: -25.56%
• Pretax Margin: -25.24%
• Return on Equity: -22.11%
• Return on Assets: -13.53%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 5.70
• Quick Ratio: 5.65

Sales & Book Value

• Annual Sales: $287.61 million
• Price / Sales: 28.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 43.99

Miscellaneous

• Outstanding Shares: 266,264,000
• Free Float: 252,764,000
• Market Cap: $8.32 billion
• Optionable: Optionable
• Beta: 1.18